Downloads provided by UsageCounts
FORMULATIONS PORTFOLIO LISTED IN THIS DATASET INCLUDES BCL-2 EXPRESSION INHIBITORS, CYCLIN B1 & D2 INHIBITORS, Hıf-10 SUPPRESSIVE AGENTS, TNF-A & NF-KAPPA B COX-2 INTERLEUKIN-6 SUPPRESSIVE AND IMMUNOMODULATIVE AGENTS FOR AUTOIMMUNE DISEASES, FMO3 SUPPRESSIVE ANALGESIC AGENTS, THYROGENIC & THYROMODULATORY AGENTS, RNA POLYMERASE & DNA POLYMERASE & VIRAL DNA GYRASE SUPPRESSIVE ANTIVIRAL AGENTS, TOPOISOMERASE I & II, RIBONUCLEOTIDE REDUCTASE SUPPRESSIVE ANTIBACTERIAL AGENTS, GLUT4 TRANSLOCATIVE ANTIDIABETIC AGENTS AND MANY OTHER INNOVATIVE FORMULATIONS WITH NOVEL MECHANISMS OF ACTION. Inventors: Erdal Can Alkoclar & Metehan Yesil
Patented Formulation, Bioceutical Innovation
Patented Formulation, Bioceutical Innovation
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
| views | 5 | |
| downloads | 7 |

Views provided by UsageCounts
Downloads provided by UsageCounts